Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

World Hepatitis Summit highlights need to develop national programmes that can eliminate viral hepatitis

Participants at the first-ever World Hepatitis Summit will urge countries to develop national programmes that can ultimately eliminate viral hepatitis as a problem of public health concern.

2 Sep 2015

TGen scientists identify potential gene associated with NAFLD-related liver damage

In a first-of-its-kind exploratory study, the Translational Genomics Research Institute has identified a potential gene associated with the initiation of the most common cause of liver damage.

2 Sep 2015

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bile duct cancer is rare and is usually detected too late. Often only extensive liver surgery can help or, in rare cases, liver transplantation. But which patients will benefit from surgery and which will not, because their risk of cancer recurrence is too high? With the oncogene MACC1 as a biomarker, physicians for the first time have a tool to decide which treatment option is best for patients with Klatskin carcinoma, one type of bile duct cancer.

1 Sep 2015

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Regen BioPharma, Inc. announced today development of a novel means of delivering its patented (US Patent 8,263,571) gene silencing nucleic acid, RGBP-248, to liver tumors utilizing a clinically approved formulation as delivery system. The product in development overcomes previous hurdles with gene silencing therapeutics in which the gene silencing drug had to be delivered throughout the whole body.

31 Aug 2015

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2015 and updates on its drug development programs.

28 Aug 2015

Researchers identify new virus that plays role in rare type of liver cancer

More than a cause of a simple infection, viruses are often involved in the development of serious diseases. Such is the case with liver cancer, which often develops in an organ that has been weakened by hepatitis B or C virus.

28 Aug 2015

New data shows liver cancer has significantly increased in Queensland since the mid-90s

Incidence rates of the most common type of liver cancer have significantly increased in Queensland since the mid-90s, new data shows.

24 Aug 2015

Tiny nanocrystals could be used in advanced medical imaging technologies to light up cancer cells

Researchers in China have developed tiny nanocrystals that could be used in the next generation of medical imaging technologies to light up cancer cells.

20 Aug 2015

Multi-national group of scientists developing new test for Hepatocellular Carcinoma

A group of clinicians and geochemists are working to develop a test for the most common form of primary liver cancer, HCC (Hepatocellular Carcinoma). HCC kills over 600,000 people worldwide every year.

19 Aug 2015

Discovery allows study of naturally occurring forms of HCV in the lab

Worldwide, 185 million people have chronic hepatitis C. Since the late 1980s, when scientists discovered the virus that causes the infection, they have struggled to find ways to grow it in human cells in the lab -- an essential part of learning how the virus works and developing new effective treatments.

19 Aug 2015

Advanced liver damage in hepatitis C patients grossly underestimated and underdiagnosed

The number of hepatitis C patients suffering from advanced liver damage may be grossly underestimated and underdiagnosed, according to a study led by researchers at Henry Ford Health System and the U.S. Centers for Disease Control and Prevention.

19 Aug 2015

UC San Diego researchers discover cells that regenerate better liver tissue than ordinary liver cells

The mechanisms that allow the liver to repair and regenerate itself have long been a matter of debate. Now researchers at University of California, San Diego School of Medicine have discovered a population of liver cells that are better at regenerating liver tissue than ordinary liver cells, or hepatocytes.

14 Aug 2015

Risk of hepatobiliary cancer higher in women with intrahepatic cholestasis of pregnancy

In a new study of more than 125,000 pregnant women in Sweden, researchers at the Sahlgrenska Academy found that the risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life is higher in women with intrahepatic cholestasis of pregnancy (ICP) than in women without this condition.

12 Aug 2015

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

Dasabuvir (trade name Exviera) and the fixed-dose drug combination ombitasvir/paritaprevir/ritonavir (trade name Viekirax) have been available since January 2015 for the treatment of adults with chronic hepatitis C infection. The German Institute for Quality and Efficiency in Health Care had examined their added benefit in a dossier assessment completed in April 2015.

7 Aug 2015

Urban emergency department sees high rates of HCV infection among intravenous drug users, Baby Boomers

An urban emergency department that set up a hepatitis C testing protocol saw high rates of infection among intravenous drug users and Baby Boomers, with three-quarters of those testing positive unaware they were infected.

7 Aug 2015

Newcastle University awarded £5M for drug development research

Cancer Research UK's Drug Discovery Committee has today (Friday) awarded Newcastle University's Northern Institute of Cancer Research £5M to bring more cancer drugs to clinical trials.

7 Aug 2015

Celsion reports updated results from HEAT Study of ThermoDox in patients with primary liver cancer

Celsion Corporation, an oncology drug development company, today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as hepatocellular carcinoma (HCC).

6 Aug 2015

Delcath Systems achieves record quarterly product revenue in Q2 2015

Delcath Systems, Inc., a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces financial results for the three and six months ended June 30, 2015.

5 Aug 2015

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Galectin Therapeutics to use the BreathID test to monitor patients in a Phase II study evaluating GR-MD-02.

3 Aug 2015

Researchers demonstrate direct connection between NOX proteins and liver fibrosis

Researchers at the University of California, San Diego School of Medicine have demonstrated a direct connection between two signaling proteins and liver fibrosis, a scarring process underlying chronic liver disease, the 12th leading cause of death in the United States.

30 Jul 2015

Liver Cancer News and Research

Further Reading

World Hepatitis Summit highlights need to develop national programmes that can eliminate viral hepatitis

TGen scientists identify potential gene associated with NAFLD-related liver damage

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Researchers identify new virus that plays role in rare type of liver cancer

New data shows liver cancer has significantly increased in Queensland since the mid-90s

Tiny nanocrystals could be used in advanced medical imaging technologies to light up cancer cells

Multi-national group of scientists developing new test for Hepatocellular Carcinoma

Discovery allows study of naturally occurring forms of HCV in the lab

Advanced liver damage in hepatitis C patients grossly underestimated and underdiagnosed

UC San Diego researchers discover cells that regenerate better liver tissue than ordinary liver cells

Risk of hepatobiliary cancer higher in women with intrahepatic cholestasis of pregnancy

IQWiG examines added benefit of dasabuvir and ombitasvir/paritaprevir/ritonavir in different patient groups

Urban emergency department sees high rates of HCV infection among intravenous drug users, Baby Boomers

Newcastle University awarded £5M for drug development research

Celsion reports updated results from HEAT Study of ThermoDox in patients with primary liver cancer

Delcath Systems achieves record quarterly product revenue in Q2 2015

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Researchers demonstrate direct connection between NOX proteins and liver fibrosis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News